• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic wins CMS coverage for Micra leadless pacer

Medtronic wins CMS coverage for Micra leadless pacer

January 26, 2017 By Fink Densford

Medtronic's Micra TPSMedtronic (NYSE:MDT) said today the U.S. Centers for Medicare and Medicaid Services released a National Coverage Determination which will cover leadless cardiac pacemakers, including the company’s Micra TPS.

With the designation, Medicare patients will have access to Fridley, Minn.-based Medtronic’s Micra through Medicare’s policy of Coverage with Evidence Development, the company said.

The Micra transcatheter pacing system, which at 1/10th the size of a conventional pacemaker is roughly the size of a large vitamin, is designed to be implanted via catheter in the right ventricle to deliver single-chamber pacing, Medtronic said. The Micra device has an estimated 12-year battery life and is approved as safe for full-body MRI scans, the company said.

The CED policy requires additional evidence to be collected as a condition of the coverage. The decision will provide coverage when procedures with leadless devices are performed in FDA-approved studies and prospective longitudinal studies cleared by CMS, Medtronic said.

Medtronic said it will seek coverage of the existing FDA-approved Micra Post-Approval study as well as a new study tracking longitudinal data in the Medicare population. The company said coverage for the device will be effective upon approval of the studies by CMS.

“Medtronic is pleased with the CMS decision to cover leadless pacemakers, which will allow broad patient access to this novel, minimally invasive pacemaker technology through an innovative approach to evidence and data collection to address research questions identified by CMS. We are working closely with CMS to ensure patient access to the Micra TPS as quickly as possible under this decision,” Medtroinc cardiac rhythm and heart failure prez Dr. John Liddicoat said in a press release.

Micra won CE Mark approval in the European Union in April 2015 and landed FDA approval a year later.

Last August, Medtronic touted 12-month results for its Micra leadless pacemaker, released at the annual meeting of the European Society of Cardiology in Rome, showing a vastly lower safety profile than conventional implanted pacemakers.

The device beat the safety and efficacy endpoints in trial results released in November 2015, showing a 99.2% successful implantation rate and a freedom-from-major-complications rate of 96%, which the company said was 51% lower than the rate for conventional pacemakers.

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Structural Heart Tagged With: Centers for Medicare and Medicaid Services (CMS), Medtronic

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy